Channavix Therapeutics and Peregrine BioVentures are developing two patent families related to long-lasting, non-opioid, non-addictive pain therapeutics.
'I would like to express our university’s solidarity with UB’s Iranian students and faculty as well as our concern for the safety and liberty of their loved ones in their home country,' he says.
A new book explores how nine countries address the issue of educational inequity, sharing critical analysis of the school reform policies employed across five continents.
Study shows the low-cost catalyst can be a viable alternative to platinum that has stymied commercialization of the eco-friendly fuel for decades because it’s so expensive.